Across TCGA pan-cancer cohorts, TTC26 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TTC26 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TTC26 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TTC26 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC and LIHC are the cancer types where TTC26 Mutation most reproducibly stratifies survival.